NASDAQ$SYRE
Spyre Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Aeglea BioTherapeutics reported third quarter 2023 financial results and provided a corporate update.
Aeglea BioTherapeutics reported a net loss of $40.1 million for the third quarter of 2023, with R&D expenses totaling $24.7 million and G&A expenses totaling $8.6 million. The company's cash and cash equivalents, marketable securities, and restricted cash totaled $204.9 million as of September 30, 2023.
- SPY001 is on track for an expected IND filing in the first half of 2024.
- SPY002 is on track for expected IND filing in the second half of 2024.
- Stockholder vote scheduled for November 21 to allow conversion of preferred stock to common stock.
- Strengthened leadership team with the appointments of Scott Burrows as Chief Financial Officer and Heidy King-Jones as Chief Legal Officer and Corporate Secretary.
Headline financials
Revenue & EPS history
Spyre · Revenue · Quarterly
$0
Forward guidance
Aeglea is advancing a pipeline of antibody therapeutics with the potential to transform the treatment of IBD. Aeglea’s approach combines novel antibody engineering, rational therapeutic combinations, and precision immunology with the goal of maximizing efficacy, safety, and convenience of treatments for IBD. The company is developing antibodies targeting α4β7, TL1A, and IL-23.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
44%
17 / 39 earnings
Positive
+14.6%
Q4 2023
Best reaction
-10.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +7.6% | +3.6% | |
| Q3 2025 | +0.5% | +4.6% | +49.4% | |
| Q1 2025 | -2.0% | -0.7% | +13.2% | |
| Q4 2024 | +7.2% | +6.0% | -2.3% | |
| Q3 2024 | +5.6% | -4.4% | -27.7% | |
| Q2 2024 | -3.0% | -6.6% | +7.4% | |
| Q1 2024 | +11.8% | +19.0% | +2.0% | |
| Q4 2023 | +14.6% | +44.3% | +45.3% | |
| Q3 2023 | -2.2% | +10.8% | +102.2% | |
| Q2 2023 | -10.3% | -12.0% | +6.7% | |
| Q1 2023 | -6.6% | -9.1% | -18.3% | |
| Q4 2022 | -0.3% | +2.0% | -26.6% | |
| Q3 2022 | -9.0% | +3.7% | -59.0% | |
| Q2 2022 | +7.7% | +5.9% | +33.3% | |
| Q1 2022 | -10.9% | -5.8% | -60.0% | |
| Q4 2021 | +0.4% | -14.6% | +14.2% | |
| Q3 2021 | -5.4% | -5.8% | -22.5% | |
| Q2 2021 | -0.6% | -3.3% | +12.1% | |
| Q1 2021 | +2.2% | +4.4% | -8.1% | |
| Q4 2020 | +1.7% | +9.7% | +5.3% | |
| Q3 2020 | +4.5% | +22.1% | +3.5% | |
| Q2 2020 | -6.7% | -4.7% | +3.2% | |
| Q1 2020 | +10.6% | -4.5% | +24.0% | |
| Q4 2019 | -8.3% | -13.2% | -40.2% | |
| Q3 2019 | -4.3% | -2.2% | -4.1% | |
| Q2 2019 | -4.1% | -3.8% | -0.5% | |
| Q1 2019 | -1.9% | -2.1% | -8.7% | |
| Q4 2018 | -0.7% | +3.1% | +8.8% | |
| Q3 2018 | +0.2% | -13.0% | -13.3% | |
| Q2 2018 | +4.8% | +1.2% | -3.4% | |
| Q1 2018 | +3.5% | +0.6% | +4.0% | |
| Q4 2017 | -1.4% | +23.7% | +20.5% | |
| Q3 2017 | -4.9% | +4.5% | +0.0% | |
| Q2 2017 | -6.3% | -7.2% | +34.8% | |
| Q1 2017 | -2.2% | -2.0% | -43.4% | |
| Q4 2016 | -4.4% | -6.9% | -8.7% | |
| Q3 2016 | -1.2% | +1.3% | -7.5% | |
| Q2 2016 | +1.1% | -1.9% | +48.2% | |
| Q1 2016 | +0.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro